Clinical Trial Update: Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule [Phase 2]

View source ↗

Summary

A Phase 2 study assessed the efficacy of a daily Lactobacillus reuteri NCIMB 30242 probiotic capsule in adults with hypercholesterolemia; the trial is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Lactobacillus reuteri NCIMB 30242 probiotic capsule (Lactobacillus reuteri NCIMB 30242)

Snippet

Sponsor: Micropharma Limited | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED